The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Rechallenge can lead to near-fatal or fatal relapse of AE/ILD
Publications
Li MSC, Lee KWC, Mok KKS, Loong HHF, Lam KC, Mok FST, Chan LL, Lau YM, Chan KP, Ng JTY, Wong WKY, Lam BHW, Chen ACC, Lee MMP, Chen OH, Mok TSK
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease.
JTO clinical and research reports 2024 Apr;5;100648 — 2024 Apr — 100648